120 related articles for article (PubMed ID: 19880436)
1. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors.
Schmid P; Kiewe P; Possinger K; Korfel A; Lindemann S; Giurescu M; Reif S; Wiesinger H; Thiel E; Kühnhardt D
Ann Oncol; 2010 Mar; 21(3):633-639. PubMed ID: 19880436
[TBL] [Abstract][Full Text] [Related]
2. Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial.
Arnold D; Voigt W; Kiewe P; Behrmann C; Lindemann S; Reif S; Wiesinger H; Giurescu M; Thiel E; Schmoll HJ
Br J Cancer; 2009 Oct; 101(8):1241-7. PubMed ID: 19773753
[TBL] [Abstract][Full Text] [Related]
3. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
Stupp R; Tosoni A; Bromberg JEC; Hau P; Campone M; Gijtenbeek J; Frenay M; Breimer L; Wiesinger H; Allgeier A; van den Bent MJ; Bogdahn U; van der Graaf W; Yun HJ; Gorlia T; Lacombe D; Brandes AA
Ann Oncol; 2011 Sep; 22(9):2144-2149. PubMed ID: 21321091
[TBL] [Abstract][Full Text] [Related]
4. First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors.
Araki K; Kitagawa K; Mukai H; Mukohara T; Kodama K; Ando Y; Narabayashi M; Minami H; Mera K; Sasaki Y
Invest New Drugs; 2012 Dec; 30(6):2327-33. PubMed ID: 22139065
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.
DeConti RC; Algazi AP; Andrews S; Urbas P; Born O; Stoeckigt D; Floren L; Hwang J; Weber J; Sondak VK; Daud AI
Br J Cancer; 2010 Nov; 103(10):1548-53. PubMed ID: 20924376
[TBL] [Abstract][Full Text] [Related]
6. Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.
Morrow PK; Divers S; Provencher L; Luoh SW; Petrella TM; Giurescu M; Schmelter T; Wang Y; Hortobagyi GN; Vahdat LT
Breast Cancer Res Treat; 2010 Oct; 123(3):837-42. PubMed ID: 20697802
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.
Rustin G; Reed N; Jayson GC; Ledermann JA; Adams M; Perren T; Poole C; Lind M; Persic M; Essapen S; Gore M; Calvert H; Stredder C; Wagner A; Giurescu M; Kaye S
Ann Oncol; 2011 Nov; 22(11):2411-2416. PubMed ID: 21372124
[TBL] [Abstract][Full Text] [Related]
8. Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.
Heigener DF; von Pawel J; Eschbach C; Brune A; Schmittel A; Schmelter T; Reck M; Fischer JR
Lung Cancer; 2013 Jun; 80(3):319-25. PubMed ID: 23522488
[TBL] [Abstract][Full Text] [Related]
9. Sagopilone, a microtubule stabilizer for the potential treatment of cancer.
Galmarini CM
Curr Opin Investig Drugs; 2009 Dec; 10(12):1359-71. PubMed ID: 19943207
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases.
Freedman RA; Bullitt E; Sun L; Gelman R; Harris G; Ligibel JA; Krop IE; Partridge AH; Eisenberg E; Winer EP; Lin NU
Clin Breast Cancer; 2011 Dec; 11(6):376-83. PubMed ID: 21697017
[TBL] [Abstract][Full Text] [Related]
11. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.
Hoffmann J; Vitale I; Buchmann B; Galluzzi L; Schwede W; Senovilla L; Skuballa W; Vivet S; Lichtner RB; Vicencio JM; Panaretakis T; Siemeister G; Lage H; Nanty L; Hammer S; Mittelstaedt K; Winsel S; Eschenbrenner J; Castedo M; Demarche C; Klar U; Kroemer G
Cancer Res; 2008 Jul; 68(13):5301-8. PubMed ID: 18593931
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors.
Zhang P; Sun M; Qiu R; Tang L; Dou G; Xu B
Cancer Chemother Pharmacol; 2011 Oct; 68(4):971-8. PubMed ID: 21305287
[TBL] [Abstract][Full Text] [Related]
13. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
Hoffmann J; Fichtner I; Lemm M; Lienau P; Hess-Stumpp H; Rotgeri A; Hofmann B; Klar U
Neuro Oncol; 2009 Apr; 11(2):158-66. PubMed ID: 18780814
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.
McMeekin S; Patel R; Verschraegen C; Celano P; Burke J; Plaxe S; Ghatage P; Giurescu M; Stredder C; Wang Y; Schmelter T
Br J Cancer; 2012 Jan; 106(1):70-6. PubMed ID: 22108514
[TBL] [Abstract][Full Text] [Related]
15. Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer.
Gauler TC; Christoph DC; Fischer J; Frickhofen N; Huber R; Gonschorek C; Roth K; Giurescu M; Eberhardt WE
Eur J Cancer; 2013 Jul; 49(11):2461-8. PubMed ID: 23692812
[TBL] [Abstract][Full Text] [Related]
16. Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas.
Silvani A; Gaviani P; Fiumani A; Scaioli V; Lamperti E; Eoli M; Botturi A; Salmaggi A
J Neurooncol; 2009 Oct; 95(1):61-64. PubMed ID: 19381446
[TBL] [Abstract][Full Text] [Related]
17. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
Hammer S; Sommer A; Fichtner I; Becker M; Rolff J; Merk J; Klar U; Hoffmann J
Clin Cancer Res; 2010 Mar; 16(5):1452-65. PubMed ID: 20179216
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.
Shimizu T; Yamamoto N; Yamada Y; Fujisaka Y; Yamada K; Fujiwara Y; Takayama K; Tokudome T; Klimovsky J; Tamura T
Cancer Chemother Pharmacol; 2008 Apr; 61(5):751-8. PubMed ID: 17594093
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Campone M; Berton-Rigaud D; Joly-Lobbedez F; Baurain JF; Rolland F; Stenzl A; Fabbro M; van Dijk M; Pinkert J; Schmelter T; de Bont N; Pautier P
Oncologist; 2013; 18(11):1190-1. PubMed ID: 24105751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]